International Symposium on Minimal Residual Cancer 2025 will be held from May 7-9, 2025 at Nice, France.
The upcoming international meeting is a fantastic opportunity to gather for three days to discuss the latest advancements in the use of liquid biopsies in cancer patients. This event will focus on clinical applications, specifically how liquid biopsy can guide treatment decisions in immuno-oncology and targeted therapies. Special sessions will explore new approaches in minimal residual disease detection, early cancer detection and screening, as well as monitoring disease progression through blood samples to track resistance mechanisms to various treatments.
The congress will also feature fundamental and translational presentations on different liquid biopsy components, including Circulating Tumor Cells, exosomes, miRNA, and circulating free DNA. Additionally, the future potential of liquid biopsy will be discussed. Supported by the European Liquid Biopsy Society (ELBS) and the Institute RespirERA in Nice, the meeting will include plenary sessions led by international experts in liquid biopsy and cancer biology. The ISMRC will also offer young investigators a platform to present their work, with selected oral and poster presentations receiving awards for excellence.
